On the recordJuly 31, 2019
Madam President, there is too much secrecy in drug pricing, particularly in who benefits from rebates. Not all rebates are created equal in the Medicaid Drug Rebate Program. Rebate obligations for brand-name drugs are currently based on both brand-name and authorized generic drug sales. That means brand-name drug manufacturers pay less in rebate obligations. The bipartisan legislation I introduced with Senator Wyden fixes this. It ensures that brand-name drug manufacturers pay--like common sense ought to dictate--brand-name rebates. This reduces gaming in the system to make sure authorized generics come to market for a purpose related to patient access, not just to lower brand-name rebate obligations. Transparency brings accountability, and with transparency and accountability, the market works better, competition works better, and in the end, gets the price of drugs down. I yield the floor. I suggest the absence of a quorum. The PRESIDING OFFICER. The clerk will call the roll. The legislative clerk proceeded to call the roll. Mr. McCONNELL. Madam President, I ask unanimous consent that the order for the quorum call be rescinded. The PRESIDING OFFICER. Without objection, it is so ordered. ____________________





